DVA vs VMD
DVA: DaVita is a specialized healthcare provider focused on delivering life-sustaining dialysis and integrated kidney care services to patients with chronic kidney failure. VMD: Viemed provides home-based respiratory, chronic care, and women's health services with clinical practitioners delivering therapy and equipment rental to patients across all 50 US states.
Side-by-side fundamentals
| Metric | DVA | VMD | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $188.69 | $9.82 | |
| Market cap as of 2026-08-06 | $12.1B | $376M | |
| P/E as of 2026-08-06 | 15.17 | 25.54 | DVA lower |
| PEG as of 2026-08-06 | 7.01 | 1.00 | VMD lower |
| Net margin as of 2026-08-06 | +5.7% | +5.2% | DVA higher |
| Gross margin as of 2026-08-06 | +32.5% | +57.6% | VMD higher |
| Operating margin as of 2026-08-06 | +15.0% | +8.2% | DVA higher |
| ROE as of 2026-08-06 | +181.2% | +10.7% | DVA higher |
| ROA as of 2026-08-06 | +4.5% | +7.6% | VMD higher |
| Debt / equity as of 2026-08-06 | 77.99 | 0.06 | VMD lower |
| Revenue growth (YoY) as of 2026-08-06 | +6.7% | +23.1% | VMD higher |
| Revenue CAGR (3y) SEC XBRL | +5.5% | +24.9% | VMD higher |
| Beta as of 2026-08-06 | 0.80 | 1.05 | |
| 1-year return as of 2026-08-05 close | +34.3% | +55.4% | VMD higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.